Vanda Pharmaceuticals Inc.

$10.22 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.

Stock Analysis

last close $10.22
1-mo return 1.1%
3-mo return -8.6%
avg daily vol. 570.6T
52-week high 21.86
52-week low 9.24
market cap. $560M
forward pe 34.1
annual div. -
roe 3.7%
ltg forecast -
dividend yield -
annual rev. $266M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe